Tags : Psoriatic Arthritis


Eli Lilly to Present Data of Taltz (ixekizumab) for Patients

Shots: Eli Lilly shared new results from a subgroup analysis of the P-IIIb/IV, 52-wks. SPIRIT-H2H study assessing Taltz vs Humira (adalimumab) in biologic-naïve patients with active PsA with 1EPs as ACR50 & PASI 100 @24wks. The study compares Taltz and Humira in subgroups of patients on monothx./ concomitant MTX/ concomitant MTX along with csDMARD including […]Read More


Amgen Receives Health Canada’s Marketing Authorization Transfer of Otezla for

Shots: Health Canada’s marketing authorization transfer of Otezla from Celgene follows Amgen’s acquisition of the global rights of Otezla completed in Nov’2019 The addition of Otezla bolster Amgen’s portfolio of innovative biologics and biosimilar products and complements its expertise in mod. to sev. PsO and active PsA Otezla is a selective PDE4 inhibitor, inhibiting the […]Read More


AbbVie Reports Results of Rinvoq (upadacitinib) in P-III SELECT-PsA 2

Shots: The P-III SELECT-PsA 2 study involves assessing of Rinvoq (15/30mg) vs PBO in adult patients with active psoriatic arthritis who have responded inadequately to one or more biologic disease-modifying anti-rheumatic drugs (bDMARDs) The P-III SELECT-PsA 2 study results: @12wks. patients achieved ACR20 (57%/64% vs 24%), ACR 50(32%/38% vs 5%), ACR 70 (9%/17% vs 0.5%); […]Read More


Novartis Reports Results of Cosentyx (secukinumab) in Head to Head

Shots: The P-III EXCEED study involves assessing Cosentyx (300mg) vs Humira (adalimumab, 40 mg) in 800+ biologic-naïve patients with PsA for 52wks. The P-III EXCEED results: Cosentyx narrowly missed statistical significance for superiority in ACR 20 but showed significant advantages in PsA specific endpoints, observed in a pre-specified sensitivity analysis, no new safety signals were […]Read More


AbbVie’s Skyrizi (risankizumab) Receives Japanese Ministry of Health, Labour and

Shots: The approval is based on P-II & P-III sustaIMM, ultIMMa-1 and IMMspire study results assessing Skyrizi in Japanese patients with plaque psoriasis, generalized pustular psoriasis and erythrodermic psoriasis & active psoriatic arthritis The study resulted in safe and effective results and has capabilities to improve the signs of these chronic immune-mediated diseases Skyrizi (risankizumab) […]Read More

Biosimilars Biotech

Sandoz’s Erelzi (etanercept, biosimilar) Receives Health Canada Approval for Psoriatic

Shots: The approval is based on P-III EGALITY study results assessing Erelzi (etanercept) vs Enbrel, evaluating its PK, safety and efficacy On 17 Jan, 2019 Sandoz received NOC from Health Canada for Erelzi for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis & improving physical function in adults with PsA, […]Read More